Yonhap Infomax NewsMay 18
Samchundang Pharm returns to profitability in Q1 2026 with operating profit of 2.4 billion won driven by Eylea biosimilar sales, despite production disruptions from GMP inspections and Middle East logistics challenges affecting European exports
#YonhapInfomax #SamchundangPharm #EyleaBiosimilar #Q1Earnings #OperatingProfit #BiosimilarDivision #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=121003
Yonhap Infomax NewsMay 15
Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
#YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=120657
Alteogen Wins Domestic Approval for Eylea Biosimilar 'Eyzen-F Inj'

Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries

Yonhap Infomax